Effects of Taurine on Broiler Aortic Endothelial Cells Activity and Antioxidant Ability Impired by Heat Stress In Vitro.

In order to provide a theoretical basis for the amelioration of heat stress-related diseases in broilers by taurine supplementation, the effect of taurine on the viability and antioxidant ability of aortic endothelial cells in broilers under heat stress was investigated in the present study. In this experiment, 10d healthy broilers were sacrificed, then aortic tissue was used for aortic endothelial cells isolation and cultivation. Tissue patching was used to cultivate primary broiler aortic endothelial cells. The 3rd to 5th generations of cells were used and randomly divided into five groups, including the control group (C), the heat-stressed group (HS), the Tau(HS + LTau) group, the Tau(HS + MTau) group and the Tau(HS + HTau) group. Cells were cultivated for 24 h in a cell incubator (37 °C, 5%CO2). Then heat-stressed cells were placed in a 43 °C thermostatic water bath for 6 h, followed by incubation in the cell incubator under 37°Cfor 1 h. The results were as follows (1) Based on MTT colorimetry and AO/EB staining, the activity of aortic endothelial cells was decreased, but the rate of apoptosis was increased in the HS group. Compared with the HS group, the taurine groups showed significantly higher level in relative survival rates (P < 0.05), and significantly lower apoptosis rates (P < 0.05); (2) compared to control group, LDH activity and MDA content of endothelial cells in the HS group were significantly increased (P < 0.01), while the levels of T-SOD, GSH-Px and T-AOC were significantly decreased (P < 0.01). The LDH activity and MDA content of endothelial cells were significantly lower in Tau group than those of HS group (P < 0.05), while the T-SOD activity, GSH-Px activity and T-AOC of endothelial cells were significantly increased (P < 0.05) in the taurine group. The results show that HS decreases antioxidant capacity, which causes severe oxidative damage to the endothelial cells; while taurine administration prevents the decline in LDH activity and MDA content, and increases the activity of several antioxidant enzymes, including SOD, GSH-Px and T-AOC, which implies that taurine can improve the broiler aortic endothelial cells activity and antioxidant ability under heat stress.

Effects of Taurine on Bowel Inflammatory Factor of Small Intestinal Mucosa Impaired by Heat Stress in Broilers.

This study investigated the effects of taurine on bowel inflammation resulting from heat stress in broilers, with the intent of providing insight into potential improvement of the condition of broilers. A total of 300 healthy 1 day AA broilers were selected, fed normally until day 7, and allocated randomly to 5 treatment groups, namely, the control group(C), the heat stress group(HS), the low Tau (LTau) group, the middle Tau (MTau) group and the high Tau (HTau) group, which represent low, medium and high concentrations of taurine respectively. In the study, various concentrations of taurine were added to the drinking water. The Heat Stress model was produced by maintaining Broilers in a room at 34 °C.Heat stress persisted for 6 h, 12 h, 7 days, and 14 days. The results showed that the expression levels of TNF-α, IFN-γ, and IL-1ß of the HTau group were significantly lower than that of the HS group at all time points examined (6 h, 12 h, 7 days, and 14 days) (P < 0.05). Compared with the HS group subjected to 6 h, 12 h and 14 days of heat stress, the MTau group exhibited significantly lower degrees of TNF-α and IL-1ß expression. Moreover, the expression of IFN-γ was higher in the HS group after 6 h, 12 h and 7 days of heat stress than that of the MTau group subjected to similar times of heat stress (P < 0.05).There were no significant difference among the groups at other periods of heat stress (P > 0.05).

[Quantitative approach for calculation of pharmacodynamic interactions and simulation of combined response].

OBJECTIVE: An approach is set up to calculate pharmacodynamic interaction and simulate the combined response. METHOD: An orthogonal design with 1-level = high dose and 2-level = low dose was adopted. An example of the compound with four components was applied to evaluate this quantitative approach. The bias was evaluated by the both scatter plots. RESULT: This approach can calculate the value of each component with different dose by its contribution to combined response, and the value is related to the importance of a compound. Drug interactions were evaluated among the combinations in each group. The prediction model performed well and simulated the combined response in the different of components in combination. CONCLUSION: The approach can be used in the similar research, and it also provides predictions of component combinations from the other studies by simulation.

Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation.

The First International Symposium on Quantitative Pharmacology in Drug Development and Regulatory Sciences was held this past October in Nanjing, China, marking the first time scientists from around the globe gathered to discuss topics related to quantitative pharmacology in the Far East. With the recent trend toward global drug development and clinical trials in nontraditional countries, China has been regarded by many as the next frontier for the pharmaceutical industry. Quantitative pharmacology embraces all phases of pharmaceutical research and development, providing a mechanism to bridge decision making from one phase of development to the next, and it facilitates multidisciplinary partnerships through the assembly of both data and models that describe complex biological, biopharmaceutic, and clinical settings. Efforts in China are at an early stage, but it is clear that Chinese scientists embrace the discipline and are keen to promote this methodology in the registration of new drugs in China. While challenges exist, they represent an exciting area of future collaboration.

Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method.

The pharmacokinetic-pharmacodynamic (PK-PD) relationship of the proton pump inhibitor rabeprazole in healthy Chinese volunteers was characterized via a population approach. Healthy Chinese male volunteers were enrolled in the clinical trial. Subjects were divided into three groups by their CYP2C19 genotype. Serum concentrations of rabeprazole were determined using high performance liquid chromatography (HPLC). The intragastric pH values were monitored simultaneously. Data analysis was performed using nonlinear mixed-effects modeling as implemented in the NONMEM software package. The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556). The time profiles for concentration and pH value, as well as the concentration-pH value relationship of rabeprazole in healthy Chinese volunteers were well described by the developed population PK-PD model.

XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China.

BACKGROUND: XS0601, consisting of active ingredients (Chuangxiongol and paeoniflorin), has been shown to inhibit arterial neointimal hyperplasia in animal models and in preliminary human studies. The objective of this study was to evaluate the safety and efficacy of XS0601 in preventing restenosis following percutaneous coronary intervention (PCI). METHODS: A multi-center, randomized, double-blind, placebo-controlled trial was conducted. A total of 335 patients were randomized into treatment with the oral administration of XS0601, or a placebo for 6 months after successful PCI. Angiographic follow-up was scheduled at 6 months, and clinical follow-ups performed at 1, 3 and 6 months after PCI. The primary end point was angiographic restenosis. The secondary end points were the combined incidence of death, target lesion nonfatal myocardial infarction, repeat angioplasty, and coronary artery bypass graft surgery. RESULTS: A total of 308 patients (91.9%) completed the study and 145 cases (47.1%) received angiographic follow-up. The restenosis rates were significantly reduced in the XS0601 group as compared with the placebo group (26.0% vs. 47.2%, P < 0.05), and the minimum lumen diameter (MLD) was greater [(2.08 +/- 0.89) mm for XS0601 vs. (1.73 +/- 0.94) mm for placebo, P < 0.05]. XS0601 also significantly reduced the combined incidence of major adverse cardiac event (10.4% in the XS0601 group vs. 22.7% in the placebo group, P < 0.05). The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in XS0601 group (7.1% and 11.0%) as compared with those in placebo group (19.5% and 42.9%) (P < 0.05). No significant side effects occurred within the 6-month follow-up period in the XS0601 group. CONCLUSION: Administration of XS0601 for 6 months is demonstrated to be safe and effective in reducing restenosis in post-PCI patients.

[Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].

OBJECTIVE: To compare the efficacy and safety of daily administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF), and a single subcutaneous injection of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF), a sustained-duration rhG-CSF, in chemotherapy-induced neutropenia. METHODS: In the present randomized, open-label, match and cross-over study, enrolled 104 patients with previously untreated non-small cell lung cancer (NSCLC), breast cancer or non-Hodgkin's lymphoma and with normal bone marrow function from 13 centers were randomly divided into 2 matched groups, AB and BA group. Each patient received two cycles of chemotherapy of identical regimen. In the study cycle, the patients received a single subcutaneous injection of PEG-rhG-CSF 100 microg/kg on day 3; and in control cycle, daily subcutaneous infection of rhG-CSF 5 microg x kg(-1) x d(-1) began on day 3 and continued for 14 days or until the absolute neutrophil count (ANC) became > or = 5.0 x 10(9)/L twice after it decreased to the nadir. Efficacy and safety parameters were monitored. RESULTS: The incidence rates of ANC < 1.5 x 10(9)/L in the 103 evaluable study cycles and 100 evaluable control cycles were 30.00% and 20.00% with the duration of 2.39 days and 2.35 days respectively. The incidence rates of grade 3 neutropenia were 7.77% and 7.00%; and that of grade 4 neutropenia were 5.80% and 4.00% respectively in the trial and control cycles. However, all the difference mentioned above did not reached statistical significance. None of the patients experienced febrile neutropenia. The ANC nadir was (7.55 +/- 5.25) x 10(9)/L and (8.42 +/- 5.57) x 10(9)/L (P = 0.257) respectively after receiving PEG-rhG-CSF and rhG-CSF. Compared with that of rhG-CSF group, the ANC profile of PEG-rhG-CSF group exhibited limited "overshoot" of neutrophils after the nadir. Subgroup analysis according to disease type yielded similar results. The safety profiles of the PEG-rhG-CSF and rhG-CSF groups were similar. Musculoskeletal pain or arthralgia occurred in 16.5% of the study cycles and 26.00% of the control cycles (P = 0.963), mostly mild or moderate. Other adverse effects such as fever, fatigue, dizziness, gastrointestinal effects and injection-site pain, were transient and easily manageable. CONCLUSION: A single subcutaneous injection of PEG-rhG-CSF 100 microg/kg provides neutrophil support and a safety profile comparable to regimen of daily subcutaneous injection of rhG-CSF 5 microg x kg(-1) x d(-1) in Chinese patients receiving a variety of myelosuppressive chemotherapy regimens.

A nomogram for prediction of absorption rate coefficient.

BACKGROUND: Previous studies have suggested that nomogram can simplize complicated calculations of several variables. A simple nomogram was constructed to estimate absorption rate coefficient (k(a)) by using the peak time (tpeak) and the elimination rate coefficient (k(e)) of drugs administered orally. METHODS: The nomogram was based on the plasma concentration-time (C-T) curve equation and the function relation between t(peak), k(a) and k(e). A mathematical analysis was presented for the construction of single chart nomogram. To check the degree of accuracy of the developed nomogram, we used it to analyze retrospective profiles of 46 drugs and compared the ka values obtained graphically and those calculated by numerically solving the descriptive equation. In addition, we measured the carbocisteine concentration of 18 healthy volunteers by HPLC with fluorescence detection. To analyze performance error, the measured carbocisteine concentrations were compared with predicted concentrations by the ka obtained from the nomograms along with the other pharmacokinetic parameters. RESULTS: The estimated of k(a) values from nomograms were in very close proximity with the numerical values. The performance error was as follows: median performance error (MDPE) and median absolute performance error (MDAPE) were 1.32% and 18.15%, respectively. CONCLUSIONS: The developed nomogram is accurate and reliable. The size of performance error meets the demand of clinical pharmacokinetics. Therefore, the nomograms can offer another convenient and easy method for rational individualized dosage regimens.

[Compound nylestriol tablet to prevent bone loss in osteoporotic rats].

OBJECTIVE: To investigate the effects of compound nylestriol tablet (CNT), containing nylestriol and levonorgestrel with a ratio of 1:0.3) and its components on the osteoporotic rat model induced by retinoic acid (RA) and ovariectomy (OVX). METHODS: We randomly divided 144 female SD rats (aged 7-month-old) into 12 groups (12 in each). In addition, 120 female SD rats aged 4-month were randomly divided into 10 groups (10 in each). Three dosage levels of CNT (0.039, 0.117 and 0.39 mg/kg body weight, daily), nylestriol (NYL, 0.30, 0.09 and 0.03 mg/kg body weight, daily) and levonorgestrel (LEV, 0.09, 0.027 and 0.009 mg/kg body weight, daily) were designed to prevent the bone loss of the osteoporotic rat model induced by RA and OVX respectively. Serum total calcium (Ca), phosphate (Pi), ALP, triglyceride (TG), total cholesterol (TC), HDL-C, total body BMD, isolated left femoral BMD and femoral Ca, and Pi after ashing were determined. RESULTS: Osteoporotic models could be induced by RA (70 mg/kg body weightdaily given intragastrically for 14 days) or by ovariectomy; CNT and its components had the preventive effects on bone loss in both models; The preventive effect of CNT was dose-dependent and stronger than its components; Many observed markers showed us the levels of high and moderate CNT given to be the strongest, corresponding to an optimal choice of the moderate dose CNT about one tablet per week in adult women. CONCLUSIONS: CNT therapy can prevent the bone loss of RA-induced and OVX-induced osteoporotic rats, and its therapeutic and preventive effect is better than its components used alone.

Hepatotoxicity and toxicokinetics of ketoconazole in rabbits.

AIM: To study the relationship between hepatotoxicity and toxicokinetics of ketoconazole in rabbits. METHODS: Normal rabbits were given intragastric gavage ketoconazole 40, 80, and 160 mg/kg. Ketoconazole plasma concentrations were measured by high performance liquid chromatography. Toxicokinetic parameters were determined from the plasma concentration-time data with the 3P97 software package. Activities of serum glutamate-pyruvate-transaminase and glutamate-oxalate-transaminase and hepatic histopathological changes were observed at 36 h after administration. The relationship between hepatotoxicity and toxicokinetic parameters of ketoconazole was analyzed by linear correlation. RESULTS: The concentration-time curves of three doses of ketoconazole fitted well into a two-compartment model. The proportional increase in the area under the plasma concentration-time curve (AUC) was more than that in the dose after the dose reached 80 mg/kg. Ketoconazole resulted in a marked elevation in the enzyme activities and significant damage of hepatocytes. Hepatotoxicity induced by ketoconazole was correlated to the dose, clearance (CL), maximum plasma concentration (Cmax), and most closely correlated to AUC when it was assessed by elevation transaminases in serum. CONCLUSION: The severity of ketoconazole-induced hepatotoxicity was closely related to the exposure level (AUC) of the drug.